Watching, waiting.
Merely from vapid curiosity (and no press of time), I continue to read and ponder the plethora of messages appearing. I'm not seeing anything about Anavex science; only thoughts about the impacts or or implications of "missed" revelations of trial data.
"Real" AVXL share investors are welcome to those perspectives, pro or con. Surely, until some trial data appear, it'll be more of the same. For most, nothing else to talk about.
This is a start-up biotech, without a saleable product (no revenue stream). Even "worse," the science is new, and not much known or understood. Three on-going clinical trials in humans; but when they might actually conclude and reveal their results is unknown.
I am a biologist. I've conducted research projects myself; am a leading team member of a federally-funded research project right now. We had stated, believed, that we would present our findings in three years. But, nope. Won't happen. Will take two or three years longer than we claimed. COVID-19 intervened. And ours is a field-biology, ecology project. What are the chances that a viral pandemic that can impact all humans might complicate and slow the progression of a human clinical trial of a new drug?
I've pondered the probabilities of Anavex success at each of my several AVXL purchases. I've always targeted 2023 as my year of decision. If Anavex has gained approval to sell any of their drugs by then, I'll be grinning. If not, I will have lost my money and life will continue. Biotechs involve biology which can be vagrant, variable, and blurred. To presume that clinical results can be affixed to desired or even projected calendar dates is an error. It's not an error that fogs my vision on out into 2023.
Hopeful patience....
